Jim Tananbaum Supports the New Technology in Treating Neuropsychiatric Disorders

Almost all chronic diseases like hearing problems, cancer, diabetes and tuberculosis among others have always had an objective point when looking for treatment or better ways to curtail the spread of diseases. For some reason, mental disorder has not been approached this way. Instead, it has received a subjective kind of treatment, an approach that has brought less progress in treating and diagnosing the disorder.

This is about to come to an end since Mindstrong Health is working towards a neuropsychiatric diagnosis and treatment platform that will gather information from the smartphones used daily by patients. The company is set to establish a relationship between an individual’s interaction with the smartphones and the brain activity or responses. With this approach, Mindstrong will be able to use the mood and cognitive biomarkers to establish things like speed of response, processing time attention and memory aspects of the brain.

According to INC42, This approach will form a platform through which better treatment for mental disorder will evolve. According to one of the co-founder of Mindstrong DR., Tom Insel, smartphones will bring forth a global solution to the mental disorder problem that has affected people in all parts of the world.

Mindstrong Health is going to achieve this groundbreaking approach through the help of firms such as Foresite Capita, Optum Ventures and Berggruen Holdings among others that have already come together in a round-A meeting to raise funds towards the accomplishment of this new technology. $14 million was raised in the first round, making it a big success for Mindstrong as they move to modernize the way care is given to patients. Check out Ideamensch to know more.

Foresite Capital was one of the companies that have been big contributors to health related studies, research and inventions. The company is led by Jim Tananbaum who is also the founder and CEO of the company. Dr. Jim has been in healthcare business line for over 25 years and has been included in Forbes’ Midas List of Top Tech Investors three consecutive times.

Jim’s earlier experiences include co-founding GelTex Pharmaceuticals, which introduced two drugs in the market; he also co-founded Theravance, Inc. His journey into healthcare started in Yale University where he graduated with a BS/BSEE degree and later got the Masters and M.B.A degrees from Harvard University.

Reference: http://www.businesswire.com/news/home/20170418005997/en/Foresite-Capital-Announces-CEO-Jim-Tananbaum-Named